Literature DB >> 29075985

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Rivka R Colen1,2, Takeo Fujii3, Mehmet Asim Bilen4, Aikaterini Kotrotsou5,4, Srishti Abrol5, Kenneth R Hess6, Joud Hajjar7, Maria E Suarez-Almazor8, Anas Alshawa3, David S Hong3, Dunia Giniebra-Camejo4, Bettzy Stephen3, Vivek Subbiah3, Ajay Sheshadri9, Tito Mendoza10, Siqing Fu3, Padmanee Sharma11, Funda Meric-Bernstam3, Aung Naing12.   

Abstract

We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.

Entities:  

Keywords:  Immune-related adverse event; Immunotherapy; Pneumonitis; Radiomics

Mesh:

Substances:

Year:  2017        PMID: 29075985      PMCID: PMC5924418          DOI: 10.1007/s10637-017-0524-2

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  21 in total

1.  An integrated visualization system for surgical planning and guidance using image fusion and an open MR.

Authors:  D T Gering; A Nabavi; R Kikinis; N Hata; L J O'Donnell; W E Grimson; F A Jolesz; P M Black; W M Wells
Journal:  J Magn Reson Imaging       Date:  2001-06       Impact factor: 4.813

2.  Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy.

Authors:  Hanchuan Peng; Fuhui Long; Chris Ding
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  2005-08       Impact factor: 6.226

3.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

Authors:  Mizuki Nishino; Lynette M Sholl; F Stephen Hodi; Hiroto Hatabu; Nikhil H Ramaiya
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

Review 4.  Mitigating the toxic effects of anticancer immunotherapy.

Authors:  Tara C Gangadhar; Robert H Vonderheide
Journal:  Nat Rev Clin Oncol       Date:  2014-01-21       Impact factor: 66.675

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development.

Authors:  Alexandra Cunliffe; Samuel G Armato; Richard Castillo; Ngoc Pham; Thomas Guerrero; Hania A Al-Hallaq
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-07       Impact factor: 7.038

9.  A Comparative Evaluation of Unsupervised Anomaly Detection Algorithms for Multivariate Data.

Authors:  Markus Goldstein; Seiichi Uchida
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

10.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105

View more
  40 in total

Review 1.  The role of radiology in the evaluation of the immunotherapy efficacy.

Authors:  Marco Calandri; Federica Solitro; Valeria Angelino; Federica Moretti; Andrea Veltri
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.

Authors:  Mitchell S von Itzstein; Shaheen Khan; David E Gerber
Journal:  Clin Chem       Date:  2020-06-01       Impact factor: 8.327

Review 3.  Imaging for Response Assessment in Radiation Oncology: Current and Emerging Techniques.

Authors:  Sonja Stieb; Kendall Kiser; Lisanne van Dijk; Nadia Roxanne Livingstone; Hesham Elhalawani; Baher Elgohari; Brigid McDonald; Juan Ventura; Abdallah Sherif Radwan Mohamed; Clifton David Fuller
Journal:  Hematol Oncol Clin North Am       Date:  2019-10-31       Impact factor: 3.722

Review 4.  Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.

Authors:  Minghao Wu; Yanyan Zhang; Yuwei Zhang; Ying Liu; Mingjie Wu; Zhaoxiang Ye
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

5.  Pulmonary Toxicities of Immunotherapy.

Authors:  Mehmet Altan; Linda Zhong; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Radiomics: A Path Forward to Predict Immunotherapy Response in Non-Small Cell Lung Cancer.

Authors:  Bardia Yousefi; Sharyn I Katz; Leonid Roshkovan
Journal:  Radiol Artif Intell       Date:  2020-09-30

7.  Artificial Intelligence and Radiomics in Head and Neck Cancer Care: Opportunities, Mechanics, and Challenges.

Authors:  Lisanne V van Dijk; Clifton D Fuller
Journal:  Am Soc Clin Oncol Educ Book       Date:  2021-03

8.  Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.

Authors:  Zongqiong Sun; Sheng Wang; Hongdi Du; Hailin Shen; Jingfen Zhu; Yonggang Li
Journal:  Invest New Drugs       Date:  2021-01-11       Impact factor: 3.850

Review 9.  The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up.

Authors:  Radouane El Ayachy; Nicolas Giraud; Paul Giraud; Catherine Durdux; Philippe Giraud; Anita Burgun; Jean Emmanuel Bibault
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

10.  Study on the prognosis predictive model of COVID-19 patients based on CT radiomics.

Authors:  Dandan Wang; Chencui Huang; Siyu Bao; Tingting Fan; Zhongqi Sun; Yiqiao Wang; Huijie Jiang; Song Wang
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.